KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD Corium, Inc. will lead the commercialization of AZSTARYS per the definitive collaboration and license agreement. Corium expects to make AZSTARYS commercially available in the U.S. as early as the second...
Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application $NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2...
Downtrend broken. Bullish flag on the 1 hour while trading tight with the 9 EMA. Above average volume past 2 days with no news? Leak ? This play is known for it's volatility and leaky news, market is expecting good update about the company's new Covid-19 saliva test, along with sales, revenue projections, and regulatory approvals. Either one of those will...
Merck is one of my favorite pharmaceutical companies. As far as I can tell, it a genuinely ethical and well-managed company with an above-average ESG rating. Merck has executed pretty consistently, with an average of 2% annual sales growth, 2.5% annual dividend growth, 3% annual earnings growth, and 4% annual free cash flow growth over the past several...
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. After an insider at Mersana Therapeutics bought shares following a May 2020 selloff triggered by an interim data release, the stock rallied over 400% during the next eight months. Another...
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057 1. MORF-057 well tolerated in all dose cohorts. 2. MORF-057 achieved greater than 95% mean receptor occupancy of integrin at three highest dose levels; demonstrates ability to saturate receptor 3. Data provide early clinical proof of concept for MORF-057 as...
Why Lixte Biotechnology Soared heavily on friday? It seems as though retail investors are banding behind this ultra-low float stock, lifting demand and therefore, lifting its price. the company hasn’t issued any news. Nonetheless, it seems as though the retail crowd on Wall Street is banding behind the stock. there is quite a bit of discussion about the stock...
JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) The transaction is expected to close on or before August 18, 2021 JanOne recently completed production of...
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as of merger close Registration trial for the treatment of relapsed/refractory...
ASLAN Pharmaceuticals Announces $18 Million Private Placement ASLAN today announced that it has entered into a securities purchase agreement to raise gross proceeds of approximately $18 million resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital (a Citadel company). the...
VBIV CEO Baxter said on a feb 5 2021 podcast that human trials were to begin in the next couple of weeks for their single dose monovalent covid vaccine vbi-2902, which received $56 Million from Canada to produce a vaccine. Today moderna announced forecasted sales of ~$18 Billion just from covid vaccine sales. Once VBi announces initiation of human trials for the...
Humanigen is due to present major data from Phase III trials at three conferences in mid-March. The stock is in multiple wedges, and a breakout or breakdown seems highly likely. Shares are currently trending sideways --- in my opinion, as investors await the outcomes of these events. When it comes, the move is likely to be explosive. Thus, implied volatility is...
Under the radar biotech play. Confirmed Cup & Handle breakout. Bullish MACD cross is a technical buy signal. Technical price target .30+.
Double position at 4.67 If this doesn't hit in two days 4hr chart plan will be initiated.
Potential reversal to the upside off of range lows Reward/Risk: 3.68/1 Entry: 81.94 or at a lower price Stop: 76.00 Target: 102.00 Options Play: April 16 85/90 Call Vertical
As long as the company continues to provide decent news and progress, I believe this pattern will prove itself. The market went down hard at yesterday's session and recovered strongly, I believe that SRNE weak hands were washed out in that move and now it will be easier for it to move towards the highs. If the volume goes down and the price will move...
Oncolytics initiated with a Buy at H.C. Wainwright H.C. Wainwright analyst Patrick Trucchio initiated coverage of Oncolytics Biotech with a Buy rating and $15 price target. The company is "on the cusp of demonstrating potential to upend the treatment paradigms of several cancers," Trucchio tells investors in a research note. He believes Oncolytics is well...
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have...